Clipping Board » Drug Poisoning ─ It is necessary to be aware of the toxic side effects before taking medication.
Min Sheng Daily, November 15, 2006
Reporter (Compiled by Qian Jilian / Comprehensive Foreign News Report)
The U.S. Food and Drug Administration (FDA) announced on the 13th that Roche's flu medication "Tamiflu" (see photo) will include a warning on its packaging sold in the United States, urging close monitoring of patients' mental states after taking the drug, especially in children.
"Tamiflu" is FDA-approved for treating and preventing influenza in adults and children over one year old. This medication does not prevent the flu but can shorten the duration and alleviate symptoms. Roche stated that since its launch in 1999, over 42 million people have taken this drug.
However, from the end of August last year to early July this year, there have been 103 new cases of behavioral abnormalities related to Tamiflu globally, with 95 cases occurring in Japan, including three deaths from falls, and two-thirds of the cases involved adolescents and children under 17 years old. Compared to the 126 similar cases reported from the drug's approval in 1999 to August last year, the increase is alarming. FDA officials said that although it is not yet certain whether the drug is the cause of these behavioral abnormalities, it is necessary to add a warning to the "Tamiflu" label.
The FDA issued a statement saying: "Influenza patients should be closely monitored for any signs of behavioral abnormalities immediately after taking the medication, as case reports indicate that these abnormalities appear after one or two doses." The FDA admitted that if the flu virus causes confusion, hallucinations, aggressive behavior, suicidal thoughts, and other abnormal behaviors, stopping the medication might actually endanger the patient. The FDA's Pediatric Advisory Committee will discuss medication recommendations on the 15th. The advisory panel's decision will be closely watched because "Tamiflu" has important uses in the event of an avian flu outbreak.
The package insert for "Tamiflu" sold in Japan already warns that confusion, abnormal behavior, delirium, hallucinations, delusions, convulsions, and other phenomena may occur after taking the drug, and recommends close monitoring of patients, with immediate discontinuation if abnormalities appear. Roche said there is no evidence linking Tamiflu to these psychiatric abnormalities, but they will still add new warnings to the drug sold in the United States.
Source: http:/ / times. hinet. net/ news/ ……/ recreation/ 30629831aae5. htm
Tamiflu May Cause Behavioral Abnormalities?
Reporter (Compiled by Qian Jilian / Comprehensive Foreign News Report)
The U.S. Food and Drug Administration (FDA) announced on the 13th that Roche's flu medication "Tamiflu" (see photo) will include a warning on its packaging sold in the United States, urging close monitoring of patients' mental states after taking the drug, especially in children.
"Tamiflu" is FDA-approved for treating and preventing influenza in adults and children over one year old. This medication does not prevent the flu but can shorten the duration and alleviate symptoms. Roche stated that since its launch in 1999, over 42 million people have taken this drug.
However, from the end of August last year to early July this year, there have been 103 new cases of behavioral abnormalities related to Tamiflu globally, with 95 cases occurring in Japan, including three deaths from falls, and two-thirds of the cases involved adolescents and children under 17 years old. Compared to the 126 similar cases reported from the drug's approval in 1999 to August last year, the increase is alarming. FDA officials said that although it is not yet certain whether the drug is the cause of these behavioral abnormalities, it is necessary to add a warning to the "Tamiflu" label.
The FDA issued a statement saying: "Influenza patients should be closely monitored for any signs of behavioral abnormalities immediately after taking the medication, as case reports indicate that these abnormalities appear after one or two doses." The FDA admitted that if the flu virus causes confusion, hallucinations, aggressive behavior, suicidal thoughts, and other abnormal behaviors, stopping the medication might actually endanger the patient. The FDA's Pediatric Advisory Committee will discuss medication recommendations on the 15th. The advisory panel's decision will be closely watched because "Tamiflu" has important uses in the event of an avian flu outbreak.
The package insert for "Tamiflu" sold in Japan already warns that confusion, abnormal behavior, delirium, hallucinations, delusions, convulsions, and other phenomena may occur after taking the drug, and recommends close monitoring of patients, with immediate discontinuation if abnormalities appear. Roche said there is no evidence linking Tamiflu to these psychiatric abnormalities, but they will still add new warnings to the drug sold in the United States.
Source: http:/ / times. hinet. net/ news/ ……/ recreation/ 30629831aae5. htm